Recently, Deep et al.18 demonstrated that sEVs derived from hypoxic prostate cancer cells enhanced the levels of MMP2, MMP9, and extracellular matrix proteins (FN and collagen) and increased the number of CD11b+ cells at putative PMN sites. The gene discussed is MMP9; the disease is prostate carcinoma.